Breaking Down the PAH Cost Burden

The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.

The comparative effectiveness study found that the addition of selexipag (Uptravi) to double oral therapy (DOT) reduced the risk of patients being hospitalized or having their disease progress.

Using Mendelian randomization analysis, researchers found evidence that 2 small groups of immunophenotypes are linked to either greater or lesser odds of developing pulmonary arterial hypertension (PAH).

As more researchers utilize digital technology to measure mobility in pulmonary arterial hypertension (PAH), a team calls for consistent protocols to make outcomes as meaningful as possible to patients and clinicians

Initial evidence suggests alternative approaches such as exercise, dietary modification, and psychosocial therapies may enhance traditional management of pulmonary hypertension.

An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical improvement when chemotherapy and immunotherapy were added to PAH triple therapy.